GH Research

About GH Research

GH Research PLC operates as a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders. The firm was incorporated in 2018 in Dublin, Ireland. Its primary focus is on advancing novel chemical entities, with its leading program centered on 5-MeO-DMT, a psychoactive substance being investigated for Treatment-Resistant Depression (TRD).

The company's product candidate, GH001, is an inhalable formulation of 5-MeO-DMT designed for rapid delivery and effect. This approach aims to provide a short-acting, profound therapeutic experience that could be administered in a controlled, outpatient setting. The potential benefit lies in its fast onset and short duration, which contrasts with longer-acting psychedelic compounds and could offer a more manageable treatment session for both patients and providers. GH Research also has a second product candidate, GH002, which is designed for intravenous administration. These product candidates are being investigated in clinical trials across Europe, including a Phase 2 trial in patients with TRD and a Phase 1 study in healthy volunteers.

The company was founded by a group of individuals associated with the German investment firm Apeiron Investment Group. Key figures include Christian Angermayer, who has a background in founding and investing in companies across life sciences and deep tech, and Florian Brand, who serves as the CEO of both ATAI Life Sciences and Apeiron. Their involvement suggests a strategic overlap and a shared vision for advancing mental health treatments through psychedelic-assisted therapies. The founders' experience in venture capital and life sciences has been instrumental in securing funding and guiding the company through its clinical development phases.

GH Research's business model is typical of a clinical-stage biopharmaceutical firm, where value is created by advancing drug candidates through the rigorous and expensive phases of clinical trials to eventually gain regulatory approval and commercialize the product. The company generates revenue primarily through capital raises to fund its research and development activities. For instance, GH Research successfully completed an Initial Public Offering (IPO) on the Nasdaq in June 2021, raising significant capital to finance its ongoing trials. The target market consists of individuals suffering from severe psychiatric and neurological conditions that have not responded to existing treatments.